Medical-device maker Medtronic Inc. (MDT) said Sunday it agreed to acquire its chief rival Covidien Plc (COV) in an almost-$43-billion deal, confirming reports out earlier over the weekend. The cash-and-stock transaction, the largest ever for Medtronic, values the Dublin, Ireland-based Covidien at $93.22 per share, or about $42.9 billion in total, based on Medtronic’s closing stock […]
View the full post at: Medtronic (MDT) in $43B Acquisition of Rival Covidien (COV)